Table 2.
Treatment response to intravitreal brolucizumab injection in patients with refractory neovascular AMD.
| Characteristics | Total (N = 81) | Good-response group (N = 67) | Poor-response group (N = 14) | p-value |
|---|---|---|---|---|
| Anti-VEGF injection | ||||
| Previous injections before the switch (n) | 24.5 ± 15.2 [3–72] | 25.8 ± 15.9 | 18.7 ± 9.4 | 0.034* |
| Number of anti-VEGF agents taken before (n) | 0.260† | |||
| 1 agent | 32 | 29 | 3 | |
| 2 agents | 42 | 32 | 10 | |
| 3 agents | 7 | 6 | 1 | |
| Total brolucizumab injections (n) | 5.2 ± 2.4 [2–21] | 5.3 ± 2.5 | 4.6 ± 1.5 | 0.295* |
| Follow-up period after the switch (weeks) | 41.4 ± 14.5 [12–68] | 42.9 ± 13.9 | 34.5 ± 15.7 | 0.049* |
| Interval of previous injection (weeks) | 7.5 ± 2.1 [4.0–12.5] | 7.5 ± 1.9 | 7.3 ± 2.6 | 0.641* |
| Interval of brolucizumab injection (weeks) | 10.5 ± 2.5 [8.0–25.6] | 10.8 ± 2.8 | 9.1 ± 1.1 | 0.028* |
| p < 0.001** | p < 0.001** | p = 0.187** | ||
| OCT biomarkers | ||||
| Pre-choroidal cleft, n (%) | 26 (32.1%) | 25 (37.3%) | 1 (7.14%) | 0.030ǂ |
| Polypoidal lesion (sharply peaked PED), n (%, PCV) | 31 (83.8%) | 30 (90.9%) | 1 (25.0%) | 0.008† |
| Hyper-reflective dots, n (%) | 56 (69.1%) | 44 (65.7%) | 12 (85.7%) | 0.206ǂ |
p-values for the difference between the good and poor responder groups were obtained. *Independent t-test; **Paired t-test; †Pearson Chi-squared test; ǂFisher’s exact test. Significant values are in bold.